
Telmisartan (40mg) + Hydrochlorothiazide (12.5mg)
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Medical applications
Ktel-H 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to a reduction in blood volume and peripheral resistance. The synergistic action of these two agents provides effective management of hypertension, helping to prevent complications such as stroke, myocardial infarction, and renal impairment. Ktel-H 40 is indicated for patients whose blood pressure is not adequately controlled by monotherapy. It is generally well tolerated; however, potential side effects include dizziness, hypotension, electrolyte imbalance, and increased urination. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This medication should be used under medical supervision, with caution in patients with renal or hepatic impairment, and is contraindicated in pregnancy and severe hypersensitivity to its components.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ktel-H 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Ktel-H 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Ktel-H 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Ktel-H 40 Tablet may be needed. Please consult your doctor. Use of Ktel-H 40 Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Ktel-H 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Ktel-H 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Ktel-H 40 Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Ktel-H 40 Tablet

Telmisartan (40mg) + Hydrochlorothiazide (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, leading to increased urine output and decreased blood volume.
Medical applications
Ktel-H 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to a reduction in blood volume and peripheral resistance. The synergistic action of these two agents provides effective management of hypertension, helping to prevent complications such as stroke, myocardial infarction, and renal impairment. Ktel-H 40 is indicated for patients whose blood pressure is not adequately controlled by monotherapy. It is generally well tolerated; however, potential side effects include dizziness, hypotension, electrolyte imbalance, and increased urination. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This medication should be used under medical supervision, with caution in patients with renal or hepatic impairment, and is contraindicated in pregnancy and severe hypersensitivity to its components.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ktel-H 40 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Ktel-H 40 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Ktel-H 40 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Ktel-H 40 Tablet may be needed. Please consult your doctor. Use of Ktel-H 40 Tablet is not recommended in patients with severe kidney disease.
Exercise Caution
Ktel-H 40 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Ktel-H 40 Tablet should be used with caution in patients with liver disease. Dose adjustment of Ktel-H 40 Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Ktel-H 40 Tablet















